(Q38396568)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25824455%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

review article

1 reference

title

Immune checkpoint inhibition in lymphoid disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25824455%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25824455%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Toby A Eyre

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25824455%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

English

0 references

publication date

30 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25824455%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

4 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25824455%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

170

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25824455%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25824455%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

291-304

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25824455%20AND%20SRC:MED&resulttype=core&format=json

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

4 March 2020

cites work

1 reference

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

21 January 2018

1 reference

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

21 January 2018

1 reference

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength

21 January 2018

1 reference

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

21 January 2018

1 reference

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

21 January 2018

1 reference

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

21 January 2018

1 reference

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy

21 January 2018

1 reference

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

Lenalidomide enhances anti-myeloma cellular immunity

21 January 2018

1 reference

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

21 January 2018

1 reference

Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.

21 January 2018

1 reference

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

21 January 2018

1 reference

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

21 January 2018

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.

21 January 2018

1 reference

In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses

21 January 2018

1 reference

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

21 January 2018

1 reference

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review

21 January 2018

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

21 January 2018

1 reference

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells

21 January 2018

1 reference

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

New monoclonal antibodies against B-cell antigens: Possible new strategies for diagnosis of primary cutaneous B-cell lymphomas

21 January 2018

1 reference

Foxp3-dependent programme of regulatory T-cell differentiation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.13397

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25824455%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference